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A large fraction of the world’s most
widespread and problematic pathogens,
such as the influenza virus, seem to persist
in nature by evading host immune re-
sponses by inducing immunity to geneti-
cally and phenotypically plastic epitopes
(aka antigenic variation). The more recent
re-emergence of pandemic influenza A/
H1N1 and avian H5N1 viruses has called
attention to the urgent need for more
effective influenza vaccines. Developing
such vaccines will require more than just
moving from an egg-based to a tissue-
culture–based manufacturing process. It
will also require a new conceptual under-
standing of pathogen–host interactions, as
well as new approaches and technologies
to circumvent immune evasion by patho-
gens capable of more genetic variation.
Here, we discuss these challenges, focusing
on some potentially fruitful directions for
future research.
Two important challenges for current
influenza research are to explain the
mechanisms involved in creating and
maintaining the highly restricted diversity
of epidemic strains and to develop more
broadly efficacious vaccines capable of
protecting against future epidemics. The
continued epidemiological importance of
the influenza virus derives in part from its
ability to generate new annual strains
capable of evading host immunity. This
plasticity is generally thought to occur
mostly through a combination of random
genetic mutations, associated with an error-
prone polymerase, and genetic reassort-
ment. We argue here that the observed
strain-to-strain, year-to-year variation is in
part a consequence of another important
contributor to the rapid emergence of
immune-evading variants, namely the pro-
pensity of the host immune system to
develop antibodies to immunodominant
epitopes (i.e., epitopes for which there is a
preferred immune response by the host)
located in variable regions of the viral
envelope protein(s) (e.g., HA and NA). The
interesting and paradoxical outcome of this
immunodominant epitope–antibody inter-
action is that it appears to lead to effective,
highly strain-specific antibodies while at the
same time (due partly to the proximity of
these epitopes to the conserved cell-recep-
tor binding site found on the viral envelope)
sterically interfering with the generation of
more broadly reactive antibodies [1–4].
The virus’s ability to mutate, together with
other host, ecological, and other evolution-
ary factors, still provide a chicken-and-egg
puzzle. It is not yet well understood how
these factors combine to produce the
characteristic patterns of influenza epide-
miology, including seasonality in the north-
ern and southern hemispheres, apparent
endemicity in the tropics, and a single-
trunk phylogeny for the proteins (viral
envelope-HA and surface neuraminidase-
NA) most often targeted by antibodies
[5–6]. This latter fact implies that a very
limited number of distinct strains are
responsible for epidemics at any given
time.
Thus far, several possible explanations
have been proposed for the very limited
diversity of epidemic strains (see Box 1):
that mutations occurring along one di-
mension of a presumed two-dimensional
‘‘strain space’’ may be intrinsically delete-
rious [7], that the viral infection produces
a short-lived strain-transcending immunity
[6], or that the virus may be evolving on a
phenotypically neutral network [8]. Addi-
tional insight will likely come from models
that integrate some of the features dis-
cussed in this essay and essential features
of the virus’s phenotype (particularly its
high mutability and its tendency to form
genetic clusters that are potential targets of
natural selection [9]), the host immune
response (particularly its propensity to
target variable epitopes that have differing
abilities to support viral neutralization [1–
2,4]), and host ecology to predict the
virus’s phylogeny and evolution.
The ability to predict accurately the
influenza virus phylogeny and evolution
would enable the prediction of imminent
circulating strains and assist in the devel-
opment of more effective conventional
vaccines, which primarily target variable
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effective, past and current influenza vac-
cines require a close match between the
corresponding epitopes of the vaccine
strain and those of the rapidly evolving,
circulating strains, an objective that is often
difficult to achieve. Vaccines that target
more conserved functional epitopes would
further improve on conventional vaccines
by protecting against a wider range of
strains and being effective for a longer
duration [11]. There are ongoing efforts to
design such vaccines, some of which have
already led to vaccine candidates that are
undergoing clinical trials [12]. In order to
achieve optimal breadth of coverage with
this new generation of vaccines there is a
continued need for basic research to
elucidate the reasons underlying the lack
of or poor immunogenicity of more con-
served functional domains located next to
immunodominant variable epitopes, to
explain the reduced plasticity of these
conserved epitopes, and to predict the
potential impact of sustained immune
pressure on these conserved targets.
Likely to prove central to the successful
design of a new generation of vaccines is a
more nuanced understanding of patho-
gen–host interactions. In particular, two
mechanisms of immune evasion—decep-
tive imprinting and antibody interfer-
ence—deserve greater attention. Decep-
tive imprinting, originally described as
clonal dominance [1–2] and later expand-
ed to include a more complex interaction
of immunodominance coupled to antigen-
ic variation [3,13–15], posits that patho-
gens, such as influenza, have evolved
epitopes that combine immunodomi-
nance, antigenic/genetic variation, and
other poorly understood mechanisms in-
volving immune regulation to decrease the
effectiveness of immune responses (both of
antibodies and T cells) to infection/
vaccination, allowing viral escape from
immune surveillance (see Box 2).
This insight suggests that by molecularly
modifying immunodominant epitopes in
such a way as to immune-dampen them
(called, ‘‘immune refocusing’’; see Figure 1)
as part of a vaccine strategy, it may be
possible to recruit the B and T cell
repertoires of vaccine-induced antibodies
away from ‘‘pathogen-evolved’’ immuno-
dominant deceptive epitopes to more
conserved epitopes, and thereby to poten-
tially sharply increase vaccine efficacy.
The feasibility of this approach to refocus-
ing the immune response is supported by
initial experimental studies on HIV-1 and
influenza virus [3,13,19,20].
In the case of B cell immunity to
influenza, antibody interference can con-
tribute to deceptive imprinting. Specifical-
ly, antibodies to epitopes with either zero
or low neutralization efficiencies (highly
type or strain-restricted) may sterically
interfere with antibodies to epitopes with
high neutralization efficiencies [4]. These
low-efficiency epitopes need not always be
immunodominant to significantly decrease
overall viral neutralization, as long as their
immunological sub-dominance is offset by
a compensating higher affinity of their
cognate antibodies. Essentially, because of
steric hindrance, antibodies are in a
competition to bind to viral coat proteins,
Box 1. What Limits the Diversity of Epidemic Strains?
In spite of the very high viral mutation rates, the phylogenies of the proteins that appear to be evolving under the highest
degree of immune selection pressure (such as the HA1 protein of H3N2 influenza virus), as measured by the ratio of
nonsynonymous to synonymous nucleotide changes occurring at known epitopic sites, have only a single trunk, implying a
very limited genetic diversity of those proteins and, hence, of epidemic strains, and many short branches. Here, we highlight
three proposed explanations for this peculiar phylogenetic structure
N Low effective dimensionality of the space of viral phenotypes
N Suppose, for simplicity, that the features of the viral phenotype most important for its spread among hosts are its
transmissibility and the epitopes most readily recognized by the immune system. If the effects of immune recognition of
different epitopes are not independent (e.g., due to interference among antibodies to those epitopes), then the number of
effective epitopes (and, hence, the effective dimensionality of the component of phenotype space represented by those
epitopes) would be smaller than the total number of epitopes. Further, if (i) there are only two effective epitopes and (ii) for a
particular viral genetic background and structure of host immunity, mutations to one of those epitopes (denoted epitope X)
decrease viral transmissibility, then mutations that give rise to epidemic strains would mostly occur in the other epitope. The
virus’s phylogeny would therefore contain a single trunk representing the lineage of the epidemic strains [7]. Nevertheless,
there may be a limited spread of strains carrying mutations to epitope X, which would occur on the branches of the
phylogeny, once host immunity renders the normally more transmissible strains less able to spread.
N Degeneracy of the mapping from genotypes to phenotypes
N Suppose that most mutations to a particular effective epitope have a negligible effect on immune recognition of that
epitope. Such mutations would produce a ‘‘neutral’’ network of epitope genotypes having similar immunological
phenotypes. During evolution the virus population would sample the neutral networks associated with the effective epitopes
while searching for genotypes whose phenotypes are less recognizable to the immune system. This would cause the virus’s
genetic diversity to increase. If an immunologically novel phenotype is found, then, depending on the selection pressure and
the fitness differential between that phenotype and the virus population’s modal phenotype, the virus would start sampling
the neutral network of the new genotype. The ensuing selective sweep will weed out the previously sampled genotypes,
reducing the virus’s genetic diversity—only the lineage of the particular genotype that ‘‘found’’ the fitter genotype would
survive. Over time, both the repeated sampling of phenotypically neutral networks of genotypes and the occasional selective
sweeps would produce a single-trunk viral phylogeny containing many short-lived side branches [8].
N Strain-transcending immunity
N Suppose that infection with one influenza virus subtype induces partial immunity against all subtypes with a half-life
sufficient to largely prevent the possibility of reinfection within the same influenza season. Such a heterotypic immunity
would contribute to a high rate of strain turnover and a limited diversity of co-circulating influenza strains during inter-
pandemic periods. In addition, during pandemic events heterotypic immunity might cause the elimination of an existing
subtype by a new (pandemic) subtype, depending on the level of pre-existing host immunity to the latter [6,10].
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free concentration to binding constant will
win, even if those antibodies are inefficient
at neutralizing the virus. In addition to
decreasing viral neutralization, the inter-
ference provided by low-efficiency anti-
bodies can also decrease the extent to
which a virus must mutate its high-
efficiency epitopes in order to infect a
vaccinated host or reinfect a previously
infected host. However, by identifying and
genetically modifying the low-efficiency
epitopes used in vaccines, it may be
possible to decrease such antibody inter-
ference and thereby greatly improve viral
Figure 1. Diagram of immune refocusing technology and steric antibody interference using influenza hemagglutinin (HA) trimer as
an example (modified from [3]). The molecular structures in the figure are drawn to scale to demonstrate the relative sizes of the reactants. In the
left panel, native HA containing immunodominant decoy epitopes induce type-specific antibodies shown in red. In the middle panel, the HA has
been engineered to include additional N-linked glycans at specific sites in the epitopes (alternatively, point mutations or deletions can be engineered
into these sites). In the right panel, the immune refocused HA antigen elicits broadly reactive immune responses (shown as a green antibody) and can
be used as a vaccine or to derive novel therapeutic antibodies having broad reactivity. The figure also highlights the potential impact of antibody
interference because the width of the distal surface of each Fab fragment of an antibody is comparable to the diameter of a native HA trimer,
antibodies that bind to different sites in the globular head of trimeric HA can sterically interfere with each other as previously shown (e.g., [21]). The
combination of deceptive imprinting and steric interference can produce oligoclonal, rather than polyclonal, immune responses that are largely
skewed towards the most immunodominant and variable epitopes in the pathogen.
doi:10.1371/journal.pbio.1000571.g001
Box 2. Deceptive Imprinting
The host adaptive immune system has evolved to recognize and respond preferentially to biochemical structures which are
deemed ‘‘foreign’’ or ‘‘non-self.’’ How ‘‘foreignness’’ is ultimately determined by the host immune system continues to be a
major question of immunology and takes on even more importance with the models proposed in this perspective.
Immunodominance—defined as a heightened and preferred immune response by the host to a limited set of epitopes—was
originally described in and thought to be purely a phenomenon of the major histocompatibility complex (MHC)–restricted
response genes in inbred mouse strains. Although experimental immunologists noted pronounced or unusually strong
antibody responses in certain host–antigen interactions, the idea of immunodominance was not readily applied to host–
pathogen interactions (reviewed in [16] and [17]). The importance of the theory of ‘‘deceptive imprinting’’ is that it advances
certain aspects of an earlier described phenomenon called ‘‘original antigenic sin’’ [18] (also known as the Hoskins effect) by
implying that immunodominance is the driving mechanism that operates and is selected for in pathogens in a genetically
outbred host setting.
Once immunodominance of epitopes is exploited by pathogens and placed into an immune memory of the host,
immunodominance leads to the propensity of the immune system to preferentially utilize immunological memory based on a
previous infection by a foreign entity (e.g., a virus, bacterium, or parasite) when a second slightly different version of that entity
is encountered. This leaves the immune system somewhat ‘‘trapped’’ by the first response it has made to each entity, and
unable to mount potentially more effective responses during subsequent infections. Thus, if pathogens couple cross-reactive
immunodominance (hetero-specific immunity) to strain-specific immunity and evolve these immunodominant epitopes
structurally next to highly conserved functional domains needed by the virus to infect host cells, the pathogens would elicit a
host immune response that is mostly directed to less protective epitopes—hence deceptive imprinting.
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neutralization efficiency antibodies [4].
Vaccines often take between 16 and 20
years to develop, and the challenge now is to
understand deceptive imprinting better and
to systematically identify and characterize
deceptive epitopes and low-efficiency, inter-
fering epitopes [3–4] in influenza and other
viruses. Progress here would enable target-
ing of both immunodominant deceptive
epitopes and low-efficiency epitopes for
genetic modification. In addition, more
studies are needed to determine whether
such genetic modifications can actually lead
to significantly greater vaccine efficacy (e.g.,
[3,19]), but there is great promise in these
understanding-driven approaches.
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